Clinical Trial: TCTLR-101

Trial Status: Open
Disease Type: Solid Tumors All
Trial ID TCTLR-101
Sponsor ID Ascendis Pharma Oncology

Phase 1/2, Open-Label, Dose Escalation and Dose Expansion Study of Transcon TLR7/8 Agonist Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor Malignancies

Locations

Fairfax Office

Learn More About This Trial

Other Relevant Trials
Trial ID 516-014
Sponsor ID Mirati

A Multicenter, Open-Label, Extension Study of the Safety and Tolerability of Sitravatinib Alone or in Combination with Other Anticancer Therapies in Patients with Advanced or Metastatic Solid Malignancies

Trial ID JBI-802-101
Sponsor ID Jubilant Therapeutics

A First-in-Human, Open-Label, Dose Escalation and Expansion Study of Orally Administered JBI-802 in Patients with Advanced Solid Tumors